Entinostat Plus Pembrolizumab Shows Promise in Previously Treated Melanoma

Cancer Network spoke with Ryan J. Sullivan, MD, about the efficacy and safety of entinostat plus pembrolizumab in patients previously treated with immunotherapy.

Related Content:

AACRMelanoma

First-Line Nivolumab Plus Ipilimumab Improves OS Versus Chemo in Patients with Metastatic Uveal Melanoma

Study Identifies Shift in Incidence of Second Primary Cancers in Patients with Metastatic Melanoma

FDA Grants Orphan Drug Designation to PVSRIPO for Treatment of Advanced Melanoma